Alzheimer's disease: a review of the disease, its epidemiology and economic impact

被引:43
作者
Alloul, K
Sauriol, L
Kennedy, W
Laurier, C
Tessier, G
Novosel, S
Contandriopoulos, A
机构
[1] Hoechst Marion Roussel Canada Res Inc, Laval, PQ H7L 4A8, Canada
[2] Univ Laval, Fac Pharm, Equipe Pharmacoepidemiol, Quebec City, PQ G1K 7P4, Canada
[3] Grp Rech Interdisciplinaire Sante, Montreal, PQ H3T 1A8, Canada
[4] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
[5] Novosel Consulting, Stoney Creek, PQ L8E 4E1, Canada
关键词
dementia; Alzheimer's disease; cost of treatment; cost of care; prevalence of Alzheimer's disease; incidence of Alzheimer's disease; epidemiology; risk factors; predictors of institutionalization;
D O I
10.1016/S0167-4943(98)00116-2
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
This article consists of a critical review of Canadian, American and European studies published between 1976 and 1997 on the subject of Alzheimer's disease (AD), and its epidemiology, patterns of care, prognostic factors, and economic impact. As the population ages in North America and Europe, significant increases in the prevalence of AD over the next decades have been projected. The elderly population represents the largest consumer group of health care resources and the management of common diseases occuring in this population will have major medical, social, and economic implications. As a result, researchers will need to integrate the ever-increasing knowledge on AD when addressing governmental and societal concerns regarding its impact. Described herein is the study findings, limitations, and differences observed following the review of the diagnostic criteria, prevalence rates, incidence rates and risk factors. Highlighted are the areas where data is lacking. To refine current models of disease progression, and better address where health care resources and new therapies would be most beneficial, the review of predictors of institutionalization and predictive models of disease progression and survival, was performed. New research questions are indicated. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:189 / 221
页数:33
相关论文
共 157 条
[31]  
CUMMINGS JL, 1996, CLIN DIAGNOSIS MANAG
[32]  
DAVIS KL, 1993, NEUROLOGY, V43, pS52
[33]   PREVALENCE AND TYPES OF DEMENTIA IN THE VERY OLD - RESULTS FROM THE CANADIAN-STUDY-OF-HEALTH-AND-AGING [J].
EBLY, EM ;
PARHAD, IM ;
HOGAN, DB ;
FUNG, TS .
NEUROLOGY, 1994, 44 (09) :1593-1600
[34]   Cognitive function and the costs of Alzheimer disease - An exploratory study [J].
Ernst, RL ;
Hay, JW ;
Fenn, C ;
Tinklenberg, J ;
Yesavage, JA .
ARCHIVES OF NEUROLOGY, 1997, 54 (06) :687-693
[35]   THE US ECONOMIC AND SOCIAL COSTS OF ALZHEIMERS-DISEASE REVISITED [J].
ERNST, RL ;
HAY, JW .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1994, 84 (08) :1261-1264
[36]   ESTIMATED PREVALENCE OF ALZHEIMERS-DISEASE IN THE UNITED-STATES [J].
EVANS, DA .
MILBANK QUARTERLY, 1990, 68 (02) :267-289
[37]   PREVALENCE OF ALZHEIMERS-DISEASE IN A COMMUNITY POPULATION OF OLDER PERSONS - HIGHER THAN PREVIOUSLY REPORTED [J].
EVANS, DA ;
FUNKENSTEIN, H ;
ALBERT, MS ;
SCHERR, PA ;
COOK, NR ;
CHOWN, MJ ;
HEBERT, LE ;
HENNEKENS, CH ;
TAYLOR, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (18) :2551-2556
[38]   Apolipoprotein E epsilon 4 and incidence of Alzheimer disease in a community population of older persons [J].
Evans, DA ;
Beckett, LA ;
Field, TS ;
Feng, L ;
Albert, MS ;
Bennett, DA ;
Tycko, B ;
Mayeux, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (10) :822-824
[39]   Alzheimer's disease and apolipoprotein E genotype in western Australia: An autopsy-verified series [J].
Fabian, VA ;
Jones, TM ;
Wilton, SD ;
Dench, JE ;
Davis, MR ;
Lim, L ;
Kakulas, BA .
MEDICAL JOURNAL OF AUSTRALIA, 1996, 165 (02) :77-80
[40]   Dementing disorders in North Italy: Prevalence study in Vescovato, Cremona Province [J].
FeriniStrambi, L ;
Marcone, A ;
Garancini, P ;
Danelon, F ;
Zamboni, M ;
Massussi, P ;
Tedesi, B ;
Smirne, S .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1997, 13 (02) :201-204